The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance

Patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) have several EGFR targeting tyrosine kinase inhibitors (TKIs) available in frontline management. However, the disease will inevitably progress over time due to acquired resistance. Longitudinal...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in oncology 2019-09, Vol.12 (3), p.765-776
Main Authors: Kibirova, Albina, Mattes, Malcolm D., Smolkin, Matthew, Ma, Patrick C.
Format: Article
Language:English
Subjects:
anti-angiogenesis
Biopsy
Case Report
Case reports
Deoxyribonucleic acid
DNA
Drug resistance
egfr
Immunotherapy
Inhibitor drugs
Lung cancer
Lymphocytes
Medical imaging
Metastasis
Monoclonal antibodies
Mutation
non-small cell lung cancer
Patients
Radiation therapy
Stains & staining
Targeted cancer therapy
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) have several EGFR targeting tyrosine kinase inhibitors (TKIs) available in frontline management. However, the disease will inevitably progress over time due to acquired resistance. Longitudinal tumor profiling for genomics guided therapy is indicated upon disease progression. It is a common scenario yet, when after failure of EGFR-TKIs, potentially actionable genomic alterations are lacking. Management of such patient is challenging with very limited options available. Combination of chemotherapy, anti-vascular/anti-angiogenic and immune-checkpoint inhibitors may become a salvage option for such patients. Here we describe a case of TKI refractory EGFR-mutant NSCLC successfully treated with carboplatin, paclitaxel, atezolizumab and bevacizumab combination with remarkable prompt tumor response.
ISSN:1662-6575
1662-6575
DOI:10.1159/000503417